Compare Ascendis Pharma A/S (ASND) vs TORM plc (TRMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs TORM plc — how do they compare? Ascendis Pharma A/S trades at $263 (market cap $17.74B), while TORM plc trades at $29.19 (market cap $2.94B). The key difference: Ascendis Pharma A/S is far larger — about 6× TORM plc's market cap, and TORM plc pays a 9.5% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | TRMD | |
|---|---|---|
Market Cap | $17.74B | $2.94B |
Sector | Health | Technology |
52-Week High | $277.18 | $34.87 |
52-Week Low | $163.32 | $17.46 |
Enterprise Value | $18.11B | $3.82B |
Dividend Yield | — | 9.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
TRMD trades at $29.48, up 5.06% today, with technical indicators showing a neutral bias and support near $28. The stock exhibits strong profitability with a 24.41% net margin and attractive valuation at a P/E of 8.65. Recent Q1 2026 earnings missed estimates but full-year guidance was raised, reflecting robust tanker market conditions. A $0.70 dividend for H1 2026 underscores shareholder returns.
Outlook remains positive given firm freight rates and strategic execution, though volatility from geopolitical factors and earnings misses pose risks. Analyst consensus is unanimously bullish, supporting upside potential if operational targets are met.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About TORM plc
TORM plc is one of the world's largest owners and operators of product tankers, specializing in the transportation of refined oil products like gasoline, jet fuel, and diesel. Operating under its integrated 'One TORM' model, the company maintains a modern, wholly-owned fleet of nearly 90 vessels. It is widely recognized by investors for its aggressive variable dividend policy, which returns a significant portion of its cash flow directly to shareholders during periods of high freight rates.
Read more on TRMD →
